Black Light Bio LLC

BioGenerator Ventures is a St. Louis-based investment firm that specializes in creating, building, and investing in companies that address critical challenges in human health and agriculture. With a portfolio spanning various sectors within the life sciences, including therapeutics, diagnostics, medical devices, research tools, agriculture, and healthcare, BioGenerator Ventures has invested $39 million into startups and has helped its portfolio companies raise over $2.6 billion in funding. Through its BioGenerator Labs engine, BioGenerator Ventures provides catalytic investments to life sciences companies, offering a suite of resources such as technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space to accelerate the growth of new ventures. With a track record of successful exits and partnerships, BioGenerator Ventures has played a crucial role in the development and maturation of companies like Geneoscopy, Medibeacon, and Benson Hill, helping them achieve significant milestones and become venture-funded and revenue-generating entities.Generated from the website

MagBiosense, Inc. is a private medical device company based in St. Louis, MO, specializing in the development of innovative diagnostic devices and assays. Their cutting-edge technology offers laboratory-quality sensitivity and the convenience of a point-of-care system, eliminating the need for additional detection steps. With a focus on infectious diseases like Zika, dengue, and West-Nile viruses, MagBiosense's serological assays have demonstrated significantly higher sensitivity and specificity compared to traditional ELISA methods. Additionally, their high sensitivity detection of cardiac troponin I enables the rapid diagnosis and rule out of heart attacks in emergency departments.Generated from the website

Medical Guidance Systems, LLC, founded in 2013 and based in Saint Louis, MO, specializes in cancer immunotherapy and nanotechnology-enabled drug delivery. The company focuses on developing targeted theragnostic solutions for patients diagnosed with poor prognosis cancers, utilizing proprietary technologies to enhance cancer cell response to treatment. Led by experienced professionals, including founder Dr. Dennis Hallahan and President Stephanie Hallahan, the team is dedicated to advancing cancer care through innovative research and development. Their pipeline includes antibodies and targeted delivery systems aimed at improving therapeutic outcomes for various cancer subtypes. Generated from the website